Bioprocessing Application Notes & Case Studies

  1. Lung Cancer Treatment By Inhaled Formulations 3/22/2021

    Dry powder inhaled formulations hold promise to allow local treatment of lung cancer with decreased chemotherapeutic-related side effects. Explore the formulation and manufacturing of a topotecan inhaled dry powder and its use in decreasing tumor size in an animal model.

  2. Novel Tool Box For EVs Therapy In Regenerative Medicine 3/22/2021

    Extracellular vesicles (EVs) derived from mesenchymal stem cells are a promising therapeutic strategy in regenerative medicine. This app note illustrates the use of our PS affinity EVs isolation technology.

  3. Transitioning Your Assay From Quantitative PCR To Droplet Digital PCR 3/19/2021

    There are similarities and differences between quantitative PCR and Droplet Digital PCR. Here we will show data that provide guidance for migrating a qPCR assay that uses a standard curve to a ddPCR assay that directly quantifies a sequence without a standard curve. Learn about how transitioning your assay from quantitative PCR to Droplet Digital PCR can be simple and provide consistent results.

  4. Optimizing Downstream Processing For An Inactivated Rabies Vaccine 3/17/2021

    This app note describes improvements made to the downstream portion of the process, specifically, use of single-use technologies and novel techniques for clarification and ultrafiltration/diafiltration. 

  5. Fc-fusion Purification Performance: Amsphere A3 Vs. Other Protein A Resins 3/14/2021

    The DBC and purification of Fc-fusion and bispecific Ab proteins are compared on A3 and other commercial Protein A resins, with a discussion of the molecular basis for A3’s high affinity for target molecules.

  6. Blazar™ Platform: Rodent Virus Panel From The BioReliance® Portfolio 3/12/2021

    Did you know about the alternative rapid method for in vivo MAP/HAP/RAP testing? Download our tech note Blazar™ Platform: Rodent Virus Panel From The BioReliance® Portfolio to learn more about our novel degenerate PCR assay designed for the detection of a broad range of adventitious agents.

  7. Process Performance Comparison Between The 50 L HyPerforma DynaDrive S.U.B. And Legacy S.U.B. Platforms 3/2/2021

    As a molecule approaches commercial launch and more is known about the potential market demand, companies are often faced with the decision to scale up or scale out their manufacturing processes. A next-generation S.U.B., the Thermo Scientific™ HyPerforma™ DynaDrive™ bioreactor, is now enabling scale-up to 5,000 L and process intensification above previous limits while continuing to leverage benefits of S.U.B.s.

  8. Using Avi-Tag Biotinylated Proteins To Determine Protein Interaction Kinetics And Affinity With Surface Plasmon Resonance 3/2/2021

    Surface plasmon resonance (SPR) is a powerful, accurate, and direct way to measure protein interactions in real-time without the need for antibodies or detection reagents. In this study, we employ R&D Systems Avi-tag Biotinylated Proteins along with streptavidin Series S chips to specifically and uniformly capture proteins in a Biacore experiment, as an alternative to chemical or amine coupling.

  9. Simplifying Charge Heterogeneity Method Development With iCE3 3/2/2021

    Imaged capillary isoelectric focusing (icIEF) on iCE3 systems is the go-to method when it comes to measuring charge heterogeneity. It lets you develop and use generic methods for multiple molecules, and gives you high-resolution charge heterogeneity peak profiles in as little as 10 minutes — cutting your development timelines. End result? Your product gets to market faster. In this application note, we’ll walk you through how simple and easy it is to develop an icIEF method and also give you a few tips for increasing method robustness.

  10. Monitoring Target Engagement In Drug Discovery: Application Of Wes To The Cellular Thermal Shift Assay 3/2/2021

    In drug discovery, confirmation of in-cell target engagement is a critical component of the drug development process. In this application note, quantitative and reproducible  CETSA data generated with ProteinSimple’s Wes™ instrument (CETSA-Wes) are presented. This assay verifies drug–target binding, and given its quantitative nature, the half maximal inhibitory concentration (IC50) is also calculated.